Filter by input type
Select all
News
Pages
Events
Filter by category
Select all
AI ANALYTICS
Mobile Apps and Internet of Things
Advancement of science
big data
Connected communities
Coronavirus
Courses and training
DIAGNOSIS
Initial Editorial
Editorials
A world in the cloud
Events
Infographics
Artificial Intelligence and Science
IoT Apps
News
Digital platforms
Social networks
Review of scientific publications
Course Summary
Synopsis of essay
Overview of reference frames
Synopsis of recent publications
Use of Digital Platforms
Filter by input type
Select all
News
Pages
Events
Filter by category
Select all
AI ANALYTICS
Mobile Apps and Internet of Things
Advancement of science
big data
Connected communities
Coronavirus
Courses and training
DIAGNOSIS
Initial Editorial
Editorials
A world in the cloud
Events
Infographics
Artificial Intelligence and Science
IoT Apps
News
Digital platforms
Social networks
Review of scientific publications
Course Summary
Synopsis of essay
Overview of reference frames
Synopsis of recent publications
Use of Digital Platforms
Scientists have developed a new protocol to generate intestinal organoids in vitro

The research was published in Nature Communications, with the title: Generation of mesenchyme free intestinal organoids from human induced pluripotent stem cells.

Researchers at Boston Medical Center developed a new way to generate groups of intestinal cells, to create laboratory disease models and thus test treatments for gastrointestinal diseases.

Scientists generated organoids from a variety of primary tissue samples such as the small intestine, stomach, colon and pancreas. By using human-induced stem cells, they were able to develop three-dimensional groups of intestinal cells known as organoids in vitro, which would function as support for treatment tests for diseases related to the gastrointestinal system.

Thanks to research developed by the CReM (Center for Regenerative Medicine) and Boston Medical Center, in which they reprogrammed adult cells in a primitive state, managed to differentiate them between intestinal cells using growth factors for organoid creation. So, this new protocol allowed cells to develop without mesenchyme, which led to the study of epithelial cells exclusively.

“Generating organoids in our lab allows us to create more accurate disease models, which are used to test treatments and therapies targeted to a specific genetic defect or tissue - and it's all possible without harming the patient,” said Gustavo Mostoslavsky PhD, co-director of CReM and professor in the gastroenterology section of Boston Medical Center. “This approach allows us to determine what treatments could be most effective, and which are ineffective, against a disease.”

“I hope that this study helps move forward our collective understanding about how diseases impact the gastrointestinal tract at the cellular level,” concluded Mostoslavsky.

Outstanding news

News by country

Share

Digital Health in the world

  • — Science Brief: Omicron (B.1.1.529) Variant/CDC updates
    See more
  • —Coronavirus resource center/Johns Hopkins
    See more
  • — Epidemiological tracing of COVID-19 contacts / Johns Hopkins Course
    See more
  • — SARS-CoV-2 infection behavior / FCS calculator
    See more
  • — Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic/ Article The Lancet
    See more
  • —Genomic Epidemiology Tracker/GISAID
    See more
  • — Mexican Genomic Surveillance Consortium
    See more
Secured By miniOrange